Propanc Biopharma Published Cancer Therapy Results
A new pilot study revealed anti-tumour efficacy in pancreatic and ovarian cancer models using a proenzyme formulation.
Updated on Oct. 14, 2026 in Cancer
Live Poll
Do you trust that new medical research consistently improves long-term health outcomes for cancer patients?
Propanc Biopharma has published a peer-reviewed pilot study in Scientific Reports detailing the effectiveness of its PRP pancreatic proenzyme formulation. The study demonstrated significant reductions in tumour weight and fibrous capsule formation in clinical models.
Why it matters
The findings suggest that the PRP formulation, which consists of a 1:6 ratio of Trypsinogen and Chymotrypsinogen A, could offer a new approach to reducing the risk of cancer recurrence and metastasis. This research provides a foundation for the company to continue developing PRP as a long-term therapy for patients.
A study cohort of 46 patients achieved a mean survival of 9.0 months, exceeding the 5.6 months mean expected survival. The treatment utilises a fixed-ratio combination of Trypsinogen and Chymotrypsinogen A at a ratio of 1:6.
The players
Propanc Biopharma
This is a Melbourne-based biopharmaceutical company focused on developing therapies for cancer patients.
Scientific Reports
This is a peer-reviewed open access journal published by Nature Portfolio that covers research from all areas of the natural sciences and clinical medicine.
The details
The research showed that PRP blocks tube formation by human umbilical vein endothelial cells while increasing epithelial markers and decreasing mesenchymal markers. In addition to laboratory results, the study noted that 19 of 46 patients survived longer than their predicted life expectancy.
Timeline
The pilot study was published in Scientific Reports on 14 October 2026.
Health Landscape
This study represents a targeted advance in the development of enzyme-based oncology therapies, marking a departure from traditional chemotherapy research. The results contribute to a growing body of evidence exploring how proenzymes can modify the tumour microenvironment.
The study offers potential new insights into management strategies for patients facing pancreatic or ovarian cancer. These findings are currently limited to early-stage research and will not immediately change standard clinical treatment protocols available to the public.
The takeaway
The study highlights the potential of proenzyme formulations to inhibit tumour growth through the regulation of epithelial and mesenchymal markers. Ongoing clinical development will be essential to determine how these findings may eventually benefit future therapeutic regimens.
Further reading
For more information on current developments, visit Australia Cancer.
More information
For further information, visit the Propanc Biopharma corporate information portal.
Live Poll
Do you trust that new medical research consistently improves long-term health outcomes for cancer patients?
